1. Home
  2. Product Information
  3. Licensing Status

Product Information

Licensing Status

Research Collaboration Programs

Program Collaboration Party Potential Disease Area
A Specific Ion Channel EA Pharma Co., Ltd. Gastrointestinal Diseases
A Specific Ion Channel Asahi Kasei Pharma Corporation Pain
A Specific Ion Channel XuanZhu Pharma Co., Ltd. Pain

Out-Licensed Programs

Program Compound Code Partnered party

Territory

EP4 Antagonist RQ-00000007
(grapiprant)
Maruishi Pharmaceutical Co., Ltd. Japan, Korea, China & Taiwan (IV formulation)
Aratana Therapeutics, Inc. WW (Animal Health)
AskAt Inc. WW (excluding Maruishi & Aratana’s Territory)
RQ-00000008 AskAt Inc. WW
Potassium-Competitive
Acid Blocker
RQ-00000004
(tegoprazan)
CJ HealthCare Corporation Korea, China, Taiwan & Southeast Asia
Ghrelin Receptor
Agonist
RQ-00000005
(capromorelin)
Aratana Therapeutics, Inc. WW (Animal Health)
5-HT4
Partial Agonist
RQ-00000009 AskAt Inc. WW
RQ-00000010 CJ HealthCare Corporation Korea, China, Taiwan, India & Southeast Asia
COX-2 Inhibitor RQ-00317076 AskAt Inc. WW
5-HT2A / D2Antagonist Ziprasidone Meiji Seika Pharma Co.,Ltd. Japan

We Create New Value-Added Drugs

RaQualia Pharma seeks to create value-added, innovative new drugs that truly contribute to society by building a large, open collaborative network with universities, public research institutions, pharmaceutical companies and venture businesses.

In order to create one new drug, an enormous amount of research funding together with the latest science, technology and know-how are essential. RaQualia is home to researchers who have specialized knowledge that is the key to achieving this objective. We put into practice our own business model, the "Integrated Open Collaboration Network Model," so that we can bring forth valuable medicines that will contribute tangibly to society.

We are confident that by doing so we can evolve our business in a way that will be useful to everyone.

Licensing Status

Licensing Out
We actively seek to license-out our portfolio. If your company is planning to expand its pipeline, you may consider using our portfolio. We offer innovative proposals that will lead your business to success.
Licensing In
We also strive to enhance our portfolio. In particular, we plan to enter into license agreements needed to expand our business in the areas of pain and gastrointestinal disease.

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics